Nucleix advances EpiCheck lung cancer platform

By staff writers

January 6, 2022 -- Nucleix has announced promising research findings in its EpiCheck next-generation sequencing (NGS) platform for detecting early-stage lung cancer. The company also announced it recently secured new funding.

Nucleix completed a side-by-side analysis that compared EpiCheck against conventional bisulfite approaches in patients with stage I lung cancer. EpiCheck revealed "many promising markers" that could indicate early-stage lung disease; meanwhile, the bisulfite approach only identified 1% of what EpiCheck detected.

The company said that the findings strengthen the firm's belief that EpiCheck is able to detect biological changes that other approaches miss.

Also, the company recently secured an additional $22 million in funding, bringing its total capital raised in 2021 to $77 million. The funds will be used to advance the next generation of its lung cancer product and drive a multicenter prospective trial for clinical validation.

Finally, Nucleix appointed Catherine Schnabel, PhD, as its chief scientific officer.

Nucleix secures $55M in funding for lung cancer test
Liquid biopsy company Nucleix has secured $55 million to advance Lung EpiCheck, an early detection lung cancer test based on methylation technology.
Nucleix showcases Bladder EpiCheck at EAU 2020
Liquid biopsy firm Nucleix touted results for its methylation-based Bladder EpiCheck urine test in two presentations at the 2020 European Association...
Nucleix highlights data for urine test in detecting bladder cancer
Liquid biopsy firm Nucleix said that its methylation-based Bladder EpiCheck urine test produced strong results for detecting high-risk, non-muscle invasive...

Copyright © 2022

Last Updated ls 1/5/2022 3:32:41 PM